Grant: Project Grant

Breast cancer remains the second deadliest cancer for Canadian women and its morbidity is largely attributed to relapse in patients from recurrent tumors. Tumors that enter a state of dormancy can eventually reactivate and often confer drug resistance and grow at an accelerated rate, hence persisting as the main hurdle in current treatment. However, the factors that promote cancer recurrence are still poorly understood. We envision that by studying the changes and characterizing the compensatory mechanisms as tumors transition from dormant to recurrent, we will uncover druggable targets that can synergize with current therapies to avert breast cancer recurrence and improve patient outcome.